![Michael Aberman](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Aberman
Directeur/Membre du Conseil chez
Halomine, Inc.
Profil
Michael S.
Aberman is the founder of Xenimmune Therapeutics, Inc. Current jobs include Director at Halomine, Inc. since 2021 and General Partner at Regeneron Ventures since 2024.
Former jobs include President & Chief Executive Officer at Quentis Therapeutics, Inc., Director-Business Development at Agenus, Inc. in 2004, Research Analyst at Credit Suisse Securities (USA) LLC from 2006 to 2010, Senior VP-Strategy & Investor Relations at Regeneron Pharmaceuticals, Inc., and Research Associate at Morgan Stanley & Co. LLC from 2004 to 2006.
Education includes an undergraduate degree from Cornell University in 1993, a doctorate from the University of Toronto in 1997, and an MBA from The Wharton School of the University of Pennsylvania in 2001.
Postes actifs de Michael Aberman
| Sociétés | Poste | Début |
|---|---|---|
Halomine, Inc.
 Halomine, Inc. Industrial SpecialtiesProcess Industries Manufactures chlorine disinfectants for surfaces and medical devices | Directeur/Membre du Conseil | 03/11/2021 |
Anciens postes connus de Michael Aberman
| Sociétés | Poste | Fin |
|---|---|---|
Credit Suisse Securities (USA) LLC (Broker)
 Credit Suisse Securities (USA) LLC (Broker) Investment Banks/BrokersFinance Provides brokerage services | Analyst-Equity | 21/03/2010 |
Morgan Stanley & Co. LLC
 Morgan Stanley & Co. LLC Investment Banks/BrokersFinance Provides brokerage services | Analyst-Equity | 31/05/2006 |
| AGENUS INC. | Corporate Officer/Principal | 01/03/2004 |
Xenimmune Therapeutics, Inc.
 Xenimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops antibody-enzyme fusion to target tumors and trigger the hyper-acute rejection | Fondateur | - |
Quentis Therapeutics, Inc.
 Quentis Therapeutics, Inc. BiotechnologyHealth Technology Develops small molecule therapeutics | Directeur Général | - |
Formation de Michael Aberman
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
98
Relations au 1er degré
10
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
Credit Suisse Securities (USA) LLC (Broker)
Credit Suisse Securities (USA) LLC (Broker) Investment Banks/BrokersFinance Provides brokerage services | Finance |
Regeneron Pharmaceuticals, Inc.
 Regeneron Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops, manufactures and commercializes medicines for diseases | Health Technology |
Agenus, Inc.
 Agenus, Inc. BiotechnologyHealth Technology Engages in the development and commercialization of technologies to treat cancers and infectious diseases | Health Technology |
Morgan Stanley & Co. LLC
Morgan Stanley & Co. LLC Investment Banks/BrokersFinance Provides brokerage services | Finance |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Toronto
 University of Toronto Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Wharton School of the University of Pennsylvania
 The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Quentis Therapeutics, Inc.
Quentis Therapeutics, Inc. BiotechnologyHealth Technology Develops small molecule therapeutics | Health Technology |
Halomine, Inc.
Halomine, Inc. Industrial SpecialtiesProcess Industries Manufactures chlorine disinfectants for surfaces and medical devices | Process Industries |
Xenimmune Therapeutics, Inc.
Xenimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops antibody-enzyme fusion to target tumors and trigger the hyper-acute rejection | Health Technology |
